Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
OS Therapies Incorporated Common Stock
(NY:
OSTX
)
1.805
+0.025 (+1.40%)
Streaming Delayed Price
Updated: 10:01 AM EDT, Sep 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
72,946
Open
1.790
Bid (Size)
1.800 (100)
Ask (Size)
1.810 (8,800)
Prev. Close
1.780
Today's Range
1.760 - 1.820
52wk Range
1.150 - 2.320
Shares Outstanding
5,847,955
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
September 15, 2026
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3...
Via
Newsfile
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
↗
September 08, 2026
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
Via
Benzinga
Performance
YTD
+34.7%
+34.7%
1 Month
+22.8%
+22.8%
3 Month
+2.0%
+2.0%
6 Month
+18.0%
+18.0%
1 Year
-18.0%
-18.0%
More News
Read More
OS Animal Health Featured in Coverage of the Disruptive Growth & Life Sciences Conference
September 08, 2026
Via
Investor Brand Network
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
September 08, 2026
Via
Newsfile
InvestorNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push
September 03, 2026
Via
Investor Brand Network
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
September 02, 2026
Via
Newsfile
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
August 17, 2026
Via
Newsfile
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
August 13, 2026
Via
Newsfile
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
July 08, 2026
Via
Newsfile
Topics
Intellectual Property
OS Therapies Third Quarter 2026 Corporate Outlook
July 06, 2026
Via
Newsfile
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
July 02, 2026
Via
Newsfile
OS Therapies Provides U.S. Regulatory Update
June 30, 2026
Via
Newsfile
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
June 26, 2026
Via
Newsfile
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
June 08, 2026
Via
Newsfile
Topics
Intellectual Property
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
June 02, 2026
Via
Newsfile
Topics
Death
Intellectual Property
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
May 29, 2026
Via
Newsfile
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
May 26, 2026
Via
Newsfile
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
May 18, 2026
Via
Newsfile
Topics
Regulatory Compliance
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
May 15, 2026
Via
Newsfile
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
May 14, 2026
Via
Newsfile
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
May 12, 2026
Via
Newsfile
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
April 30, 2026
Via
Newsfile
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
April 27, 2026
Via
Newsfile
Topics
Intellectual Property
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
April 16, 2026
Via
Newsfile
Topics
Intellectual Property
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
April 13, 2026
Via
Newsfile
Frequently Asked Questions
Is OS Therapies Incorporated Common Stock publicly traded?
Yes, OS Therapies Incorporated Common Stock is publicly traded.
What exchange does OS Therapies Incorporated Common Stock trade on?
OS Therapies Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for OS Therapies Incorporated Common Stock?
The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange
What is the current price of OS Therapies Incorporated Common Stock?
The current price of OS Therapies Incorporated Common Stock is 1.805
When was OS Therapies Incorporated Common Stock last traded?
The last trade of OS Therapies Incorporated Common Stock was at 09/16/26 10:01 AM ET
What is the market capitalization of OS Therapies Incorporated Common Stock?
The market capitalization of OS Therapies Incorporated Common Stock is 10.56M
How many shares of OS Therapies Incorporated Common Stock are outstanding?
OS Therapies Incorporated Common Stock has 11M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today